Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing literature without systematic methodology
PubMed 34449705 · doi:10.3390/neurolint13030038
What was done
This is a narrative review detailing the mechanism of action, pharmacokinetics, pharmacodynamics, and adverse effect profiles of the six major selective serotonin reuptake inhibitors (SSRIs) available in the USA: fluoxetine, citalopram, escitalopram, paroxetine, sertraline, and fluvoxamine.
What was found
The abstract states that depression affects 4.4% of the global population. It describes the common mechanism of presynaptic serotonin reuptake inhibition and notes that each SSRI has distinct pharmacokinetic, pharmacodynamic, and side effect characteristics. It highlights the black box warning for increased suicidality risk in children and young adults aged 18–24, noting that adults without certain risk factors do not appear to carry this increased risk. No specific numerical risk estimates or effect sizes are reported in the abstract.
Why it matters
It serves as an educational summary for clinicians to balance risks and benefits when selecting among distinct SSRIs, particularly concerning age-specific suicidality warnings.
Limits
This is a non-systematic narrative review providing no primary experimental data, search methodology, or quantitative risk estimates in the abstract.
Cited by
- contradicts Lexapro works by releasing serotonin and bathing the brain in more serotonin to help take the edge off stress.